Cagrilintide
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About Cagrilintide
Cagrilintide is a long-acting amylin analog being developed in combination with semaglutide (as CagriSema) for obesity and type 2 diabetes. The CagriSema combination has shown weight loss exceeding 22% in early trials, rivaling surgical outcomes. Amylin complements GLP-1 action through independent satiety pathways. It is not yet approved but represents the next frontier in pharmacological obesity treatment.
Science
Mechanism of Action
Mimics amylin, a pancreatic hormone co-secreted with insulin, to slow gastric emptying, suppress glucagon, and signal satiety through area postrema receptors — pathways distinct from and additive to GLP-1.
Dosing
Typical Protocol
0.3–2.4 mg subcutaneous injection once weekly; currently in Phase III trials as monotherapy and in CagriSema combination.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Cagrilintide is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.